Zealand Pharma (Denmark)

Recent papers from Zealand Pharma (Denmark)

1. Cancer Diagnostics Among People With Intellectual Disability—A Systematic ReviewJournal of Intellectual Disability Research · 2026
2. Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibitionJournal of Clinical Investigation · 2026
3. M2 macrophage activation in recurrent acute pancreatitis: an explorative analysis of a randomized controlled trialScandinavian Journal of Gastroenterology · 2026
4. Treatment and progression of patients in Sweden with metastatic castration-sensitive prostate cancerActa Oncologica · 2026
5. Impaired glucose tolerance and mild diabetes induce β-cell dysfunction in mice.2026
6. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 TrialsDiabetes Obesity and Metabolism · 2026
7. Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS‐1 phase 3 trialNutrition in Clinical Practice · 2026
8. Investigation of the stool microbiome of short bowel syndrome patients before and after a 24-week treatment with the glucagon-like peptide 2 analog glepaglutideClinical Nutrition ESPEN · 2026
9. Universal Baseline for in vitro Selection of Genetically Encoded Libraries2026
10. Efficacy of the Hepatotropic Peripheral CB1R Inverse Agonist TM38837 in Rat Models of Obesity and Metabolic SyndromeJournal of Molecular and Clinical Medicine · 2025
11. Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin AnalogueJournal of Medicinal Chemistry · 2025
12. Total costs of different lines of treatment in diffuse large B-cell lymphoma in Denmark – a real-world data analysisThe European Journal of Health Economics · 2025
13. Colorectal Neoplasia Pathogenesis in Normal Appearing Colonic Mucosa ‐A Perspective With Focus on Eicosanoid Signaling PathwaysCancer Medicine · 2025
14. Treatment patterns in patients with locally advanced and metastatic bladder cancer in Denmark 2015-2023 – an updated analysisActa Oncologica · 2025
15. Lipidated IL-22 Alone or Combined with Immunomodulatory Agents Improves Disease Endpoints and Promotes Mucosal Healing in a Mouse Model of Chronic Dextran Sodium Sulfate-Induced ColitisDigestive Diseases and Sciences · 2025
16. Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 YearsAmerican Journal of Clinical Dermatology · 2025
17. Assessing Hybridization-Dependent Off-Target Risk for Therapeutic Oligonucleotides: Updated Industry RecommendationsNucleic Acid Therapeutics · 2025
18. Creating Glepaglutide, the First Long-Acting GLP-2 Analogue to Enable a Ready-to-Use InjectionJournal of Medicinal Chemistry · 2025
19. Glepaglutide, a Long-Acting Glucagon-like Peptide-2 Analogue, Reduces Parenteral Support in Patients With Short Bowel Syndrome: A Phase 3 Randomized Controlled TrialGastroenterology · 2024
20. Dasiglucagon in Children With Congenital Hyperinsulinism Up to 1 Year of Age: Results From a Randomized Clinical TrialThe Journal of Clinical Endocrinology & Metabolism · 2024